Red X iconGreen tick iconYellow tick icon

Contact Details

Email
russell.scott@cdhb.health.nz
Position
Clinical Professor
Department
Department of Medicine (Christchurch)
Qualifications
BMedSc MB ChB(Otago) PhD(Monash) FRACP

Research

  • Prevention and treatment of type 1 Diabetes Mellitus
  • Adipocyte function and Insulin resistance
  • Lipid disorders and CVD
  • Endothelial function and endocrine regulation
  • Diabetes Epidemiology and health outcomes

Publications

Willis, J., Cunningham-Tisdall, C., Griffin, C., Scott, R., Darlow, B. A., Owens, N., Ferguson, J., Mackenzie, K., Williman, J., & de Bock, M. (2022). Type 1 diabetes diagnosed before age 15 years in Canterbury, New Zealand: A fifty year record of increasing incidence. Pediatric Diabetes, 23, 301-309. doi: 10.1111/pedi.13305 Journal - Research Article

Scott, R. (2020, August). What's hot in diabetes? Plenary presentation at the South General Practice Conference & Medical Exhibition (GP CME), Christchurch, New Zealand. Conference Contribution - Verbal presentation and other Conference outputs

Cao, J., Waldman, B., O'Connell, R., Sullivan, D., Gebski, V., Marschner, I., Scott, R., … on behalf of the FIELD Investigators. (2019). Baseline and short-term change in plasma uric acid on fenofibrate predict cardiovascular risk: A post hoc analysis of FIELD. Heart, Lung & Circulation, 28(Suppl. 4), (pp. S286-S287). doi: 10.1016/j.hlc.2019.06.354 Conference Contribution - Published proceedings: Abstract

Scott, R., Morgan, J., Zimmer, Z., Lam, R. L. H., O'Neill, E. A., Kaufman, K. D., … Raji, A. (2018). A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study. Diabetes, Obesity & Metabolism, 20, 2876-2884. doi: 10.1111/dom.13473 Journal - Research Article

Raal, F. J., Stein, E. A., Dufour, R., Turner, T., Civiera, F., Burgess, L., … Scott, R., … for the RUTHERFORD-2 Investigators. (2015). PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial. Lancet, 385(9965), 331-340. doi: 10.1016/S0140-6736(14)61399-4 Journal - Research Article

Back to top